U.S. Markets open in 7 hrs 2 mins
  • S&P Futures

    3,809.25
    -7.50 (-0.20%)
     
  • Dow Futures

    31,214.00
    -22.00 (-0.07%)
     
  • Nasdaq Futures

    12,643.25
    -38.50 (-0.30%)
     
  • Russell 2000 Futures

    2,200.50
    -5.30 (-0.24%)
     
  • Crude Oil

    61.78
    +0.50 (+0.82%)
     
  • Gold

    1,718.40
    +2.60 (+0.15%)
     
  • Silver

    26.29
    -0.10 (-0.37%)
     
  • EUR/USD

    1.2057
    -0.0010 (-0.0844%)
     
  • 10-Yr Bond

    1.4700
    0.0000 (0.00%)
     
  • Vix

    26.67
    +2.57 (+10.66%)
     
  • GBP/USD

    1.3959
    +0.0006 (+0.0433%)
     
  • USD/JPY

    107.1530
    +0.1510 (+0.1411%)
     
  • BTC-USD

    49,747.37
    +931.98 (+1.91%)
     
  • CMC Crypto 200

    995.27
    +7.17 (+0.73%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

STAMFORD, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 2019 Cantor Fitzgerald Global Healthcare Conference on Thursday, October 3, 2019 at 4:10 p.m. ET in New York, NY.

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in the peripheral nervous system, and on immune cells. In a Phase 3 and two Phase 2 trials, KORSUVA (CR845/difelikefalin) Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in pruritus-related quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP), and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with chronic kidney disease, atopic dermatitis, and primary biliary cholangitis.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
212-362-1200
jane.urheim@SternIR.com

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com